Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA3 | P07451 | 2/20 | 0.61 |
| ▸ | CA4 | P22748 | 2/20 | 0.61 |
| ▸ | CA6 | P23280 | 2/20 | 0.61 |
| ▸ | CA5A | P35218 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9479150 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL421078 | 1.00 | — | — | |
| SCHEMBL9478909 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL4364651 | 1.00 | — | — | |
| SCHEMBL9479475 | 1.00 | — | — | |
| SCHEMBL9479935 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL7775138 | 1.00 | DNM1 (0.61) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL947607 | 0.96 | — | — | |
| SCHEMBL359767 | 0.84 | — | — | |
| SCHEMBL25262966 | 0.78 | DNM1 (1.00) | DNM1CA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0479822-B1 | THERAPEUTIC NUCLEOSIDES | WELLCOME FOUND (GB) | 1999-08-18 | — | — | EP | claimed |
| EP-0046572-B1 | 6-QUINAZOLINESULFONYL DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1984-10-31 | — | — | EP | claimed |
| EP-0046572-A2 | 6-Quinazolinesulfonyl derivatives and process for preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-03-03 | — | — | EP | claimed |
| US-20030191086-A1 | Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof | USTAV EXPERIMENTALNI BOTANIKY AV CR | 2003-10-09 | — | — | US | disclosed |
| EP-1147108-B1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | USTAV EX BOTAN AKADEMIE VED CE (CZ) | 2003-08-13 | — | — | EP | disclosed |
| US-6552192-B1 | Inhibiting cyclin dependent kinase proteins, viruses, and immunostimulation; antimitotic, antiviral, anticancinogenic, antidegenerative, immunosuppressive | USTAU EXPERIMENTALNI BOTANIKY AV-CR (CZ) | 2003-04-22 | — | — | US | disclosed |
| EP-1147108-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000043394-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | ÚSTAV EXPERIMENTÁLNÍ BOTANIKY AV CR (CZ) | 2000-07-27 | — | — | WO | disclosed |
| EP-0479822-B1 | THERAPEUTIC NUCLEOSIDES | WELLCOME FOUND (GB) | 1999-08-18 | — | — | EP | disclosed |
| US-5260446-A | Azo dye precursors | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-09 | — | — | US | disclosed |
| EP-0433879-A2 | Aminothiazoles | BASF Aktiengesellschaft (DE) | 1991-06-26 | — | — | EP | disclosed |
| EP-0400290-A1 | 5-Amino-4-hydroxyvalerianic acid derivatives useful as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1990-12-05 | — | — | EP | disclosed |
| US-4863903-A | RENIN ENZYME INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| US-4719288-A | HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| US-4613676-A | PEPTIDES | CIBA-GEIGY CORPORATION (US) | 1986-09-23 | — | — | US | disclosed |
| EP-0144290-A2 | Substituted ethylenediamine derivatives | CIBA-GEIGY AG (CH) | 1985-06-12 | — | — | EP | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |
| US-4510307-A | 6-Quinazolinesulfonyl derivatives and process for preparation thereof | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-04-09 | — | — | US | disclosed |
| EP-0046572-B1 | 6-QUINAZOLINESULFONYL DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1984-10-31 | — | — | EP | disclosed |
| EP-0046572-A2 | 6-Quinazolinesulfonyl derivatives and process for preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191086-A1 | Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof | CDK4, CDK5, CCNI | DNM1 2605/4885CA12 3599/4885CA1 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.